Inactive Instrument

2cureX AB

Stocks

Published on 05/20/2026 at 09:05 pm +03 - Modified on 05/20/2026 at 11:50 pm +03

S&P Capital IQ

Presenter Speech
Nathaniel Hutley (Executives)

[Operator Instructions] You'll probably notice that I'm listed here as being Galen Moore. I am not Galen Moore. I'm Nat. So sorry, we've had some

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

08-25	2Curex begins the process for a listing on Spotlight	FW
08-18	2cureX Flags Delisting from Nasdaq First North Growth Market	MT
08-18	Nasdaq to delist 2Curex from First North, last trading day August 31	FW
08-18	2cureX Removed From Trading In Stockholm	RE
07-07	2Curex AB Accelerates Technical Transformation and Decentralised Inditreat Platform Development	CI
07-07	2cureX Accelerates Reintegration Into Listed Company	RE
06-25	2Curex AB Announces Board Changes	CI
05-25	2cureX AB Proposes No Dividend for the Financial Year 2025	CI
05-25	2Curex AB Announces Tonni Bülow-Nielsen Declines Re-Election as Director	CI
05-20	2cureX AB - Shareholder/Analyst Call
05-20	2cureX signs collaboration deal with StoreMyTumor	RE
05-20	2cureX AB and StoreMyTumor Sign Strategic Collaboration Agreement	CI
04-22	2cureX Raises SEK7.5 Million Through Directed Share Issue	MT
04-22	2cureX raises about SEK 7.51 mln through share issue	RE
02-27	2cureX H2 operating loss at SEK 644,000	RE

Duration

Period

Sector